The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of certolizumab plus chemotherapy in patients with stage IV lung adenocarcinomas.
 
Paul K. Paik
Honoraria - Celgene; Clovis Oncology; EMD Serono
Consulting or Advisory Role - Celgene; Clovis Oncology; EMD Serono
Research Funding - Celgene; GlaxoSmithKline
 
Juliana Eng
No Relationships to Disclose
 
Leslie Perez
No Relationships to Disclose
 
Erika Ritter
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Kenneth K. Ng
No Relationships to Disclose
 
John Joseph Fiore
No Relationships to Disclose
 
Phillip Wong
Consulting or Advisory Role - Merck
Patents, Royalties, Other Intellectual Property - Receive small annual royalty payments from the University of Washington for a monoclonal antibody that was developed during my graduate studies there.
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
Joan Massague
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; Array BioPharma; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Genentech/Roche; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)